Disney Warns France Future Blockbusters Could Bypass Cinemas

-FT https://www.ft.com/content/29fbbb2c-7eef-4b6b-8c46-f05d395f55cf

byCharles Gross

October 17, 2022

1 minute read

-FT

https://www.ft.com/content/29fbbb2c-7eef-4b6b-8c46-f05d395f55cf

PFSweb Q4 EPS $(0.04) Up From $(0.08) YoY, Sales $94.16M Beat $88.45M Estimate

By Benzinga Newsdesk

Today, 8:43 PM

PFSweb (NASDAQ:PFSW) reported quarterly losses of $(0.04) per share. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $94.16 million

PFSW

Astronics To Receive $24M In Cash From Combination Of AMJP And Asset Sale

By Benzinga Newsdesk

Today, 8:43 PM

Astronics Corporation (NASDAQ:ATRO), a leading provider of advanced technologies for global aerospace, defense and other mission critical industries, announced that it has closed on the sale of its facility in Ft.

ATRO

Fake Employee Rahul Ligma Gets Sacked From FTX Shortly After Twitter: Elon Musk Tells Benzinga He Can Come Back

By Chris Katje

Today, 8:43 PM

It’s been a rough two weeks for fictional character Rahul Ligma. In the span of a couple of weeks, Ligma was fired from both Twitter and FTX. Here’s what happened and what Tesla Inc (NASDAQ: TSLA) and Twitter CEO Elon Musk had to say.

TSLA

Immatics Reports Clinical Responses Across Multiple Solid Tumor Types In Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME

By Benzinga Newsdesk

Today, 8:43 PM

Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across

IMTX

Disney Warns France Future Blockbusters Could Bypass Cinemas

Related Posts

PFSweb Q4 EPS $(0.04) Up From $(0.08) YoY, Sales $94.16M Beat $88.45M Estimate

Astronics To Receive $24M In Cash From Combination Of AMJP And Asset Sale

Fake Employee Rahul Ligma Gets Sacked From FTX Shortly After Twitter: Elon Musk Tells Benzinga He Can Come Back

Immatics Reports Clinical Responses Across Multiple Solid Tumor Types In Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME